In a double-blind controlled study, 47 women with unexplained primary infertility were allocated at random to treatment with either bromocriptine 2 5 mg twice daily (24 patients) or placebo (23). Both groups showed a fall in serum prolactin concentrations but the reduction was much greater in the bromocriptine-treated group. Neither group showed a change in serum oestrogen or progesterone concentrations. Bromocriptine significantly reduced the duration of the follicular phase of the menstrual cycle but had no such effect on the luteal phase.
Introduction
Bromnocriptine is undoubtedly the drug of choice for infertility due to hyperprolactinaemic amenorrhoea, but its role in other forms of infertility is uncertain.' In a group of patients with ovulatory infertility who were treated with bromocriptine the cumulative conception rate greatly exceeded that in other women with a similar duration of infertility.2 Accurate interpretation of those results, however, was not possible owing to the lack of a matched control group. We report the results of a randomised, double-blind controlled trial of six months' treatment with bromocriptine 2-5 mg twice daily in patients with unexplained primary infertility.
Patients and methods
Criteria for inclusion in the trial were as follows: primary infertility for two years or more; regular menstrual cycles of under six weeks' duration; biphasic temperature charts; duration of luteal phase (number of days between first upward deflection on basal body temperature chart and first day of menstruation) exceeding 10 days; serum progesterone concentration on days 18-21 at least 25 nmol/l (7 9 ng/ml); tubal patency established by laparoscopy or hysterosalpingography (one case); normal postcoital test result; and husband's sperm count 20 x 109/1 or more. In all but one patient a normal pelvis with patent Fallopian tubes was found at laparoscopy; the single exception had tubal patency shown by hysterosalpingography. Informed consent for inclusion in the trial was obtained from both partners.
After a blood sample had been taken in the midluteal phase of the immediate pretrial cycle the women were given a numbered bottle containing tablets of either bromocriptine (2-5 mg/tablet) or placebo. They were warned about possible side effects and asked to begin treatment on the second day of their next menstrual cycle, starting with half a tablet at night with food for three nights, followed by one tablet at night with food for three nights, and then one tablet twice daily for the remainder of the trial. They were asked to return seven weeks later for review of side effects and a repeat blood test. They were seen again three and six months later, after which the trial was discontinued. The bottles containing bromocriptine and placebo tablets were numbered in random order and supplied by Dr Graham Kennedy, of Sandoz Products Limited. Allocation to treatment was thus randomised and double-blind.
Serum prolactin (expressed in terms of the VLS No 1 reference preparation), progesterone, and oestradiol concentrations were measured by radioimmunoassay.
Results
Forty-nine patients entered the trial but two were excluded because they became pregnant before starting the tablets. One of these patients had had a history of infertility for five years and the other a history for three years. Table I gives the clinical and endocrine details and numbers of conceptions in the remaining 47 patients.
There was no significant difference between the 24 patients given bromocriptine and the 23 given placebo with respect to age, duration of infertility, or husband's sperm count. Serum prolactin concentrations were normal (< 20 .tg/l) in all but two cases. One patient in the bromocriptine-treated group had a pretrial serum prolactin concentration of 39 ,ug/l that fell to under 2 ,ug/l at six weeks, and a patient in the placebo-treated group had a pretrial serum prolactin concentration of 44 ,ug/l that rose to 51 .tg/l at six weeks. In the remaining 45 patients the concentrations were log-normally distributed.
After logarithmic transformation there was a small but significant difference (P = 0 052) in mean serum prolactin concentrations between the two groups, a slightly lower value being found in the bromocriptinetreated group (table I) . There was no significant difference between the groups in the pretrial serum progesterone or oestradiol concentrations.
EFFECTS OF TREATMENT
Five women became pregnant during treatment with placebo, and seven (including the patient with a raised pretrial serum prolactin concentration) during treatment with bromocriptine. Analysis of the cumulative conception rates (calculated by the life-table method of Tietze3) showed no significant difference between the two groups (table II) . After the trial one normoprolactinaemic patient who had received placebo became pregnant in her first cycle on bromocriptine, and one patient who had received bromocriptine became pregnant in the first month after stopping treatment. The hyperprolactinaemic patient who had received placebo during the trial was subsequently given bromocriptine for nine months in a dose (2 5 mg twice daily) sufficient to reduce her serum prolactin concentration to normal but still failed to conceive.
During the trial the mean duration of the menstrual cycle in the bromocriptine-treated group was 1-2 days shorter than in the placebotreated group (P < 0 05-table I). There was no difference, however, in mean duration of the luteal phase. In the patients given bromocriptine the serum prolactin concentrations fell to below 2 ,ug/l in all but three cases (table I) ; no significant change, however, occurred in the serum oestradiol and progesterone concentrations. During treatment with placebo there was a small but significant fall in serum prolactin concentrations (mean difference after log transformation 2-3 Lg/l-P = 005; t = 208) but again no change occurred in the serum oestradiol or progesterone concentrations.
Side effects (nausea and dizziness or headaches or both) were reported by 10 patients taking bromocriptine and 12 taking placebo and persisted for up to one month in nine and eight of the patients respectively. Although generally mild, in one patient taking bromocriptine they were so severe that she withdrew from the trial after two months (table II) .
The mean age of the 12 patients who became pregnant during the trial (28 91 +SD 2-53 years) was significantly less than that of the 35 who did not conceive (31 54±2-9 years) (P<0 001; t=3 76). Those who conceived also had a significantly shorter history of infertility (3 0+SD 1 4 years v 5 31 +29 years-P=0 007; Mann-Whitney U test). Nevertheless, when the numbers of years of infertility were subtracted from the ages of the individual patients there was no though one patient conceived during the sixth month of treatment with bromocriptine, the other patient, who had received placebo, still failed to conceive after nine months' subsequent treatment with bromocriptine. In our experience the degree of hyperprolactinaemia shown by these patients, when associated with amenorrhoea, is associated with a highly favourable response to bromocriptine.9 Our results, and those of Moore et al,6 suggest that prolactin measurements, though of prime importance in amenorrhoea, have little therapeutic relevance in patients with normal ovulatory menstrual cycles. Sarris et al"°r eached a similar conclusion.
Our patients who conceived were significantly younger and had a significantly shorter history of infertility than those who did not become pregnant. These observations, which reflect the well-known effects of age and duration ofinfertility on fecundity," emphasise the importance of reporting the ages and full clinical details of patients in studies of infertility, since these factors may override any putative therapeutic procedures. Though we cannot be certain whether it was the patient's age or the duration of infertility that carried the graver prognosis, we found that subtracting the number of years of infertility eliminated the difference between the ages of those who did and those who did not conceive; this suggests that, in patients in the age range studied here, the duration of infertility carries a more serious prognosis than does age alone.
Finally, it was interesting to note the high incidence of side effects and their equal distribution in the two treatment groups. The incidence of side effects in drug trials tends to reflect the intensity with which patients are warned of them and with which they are sought, and our results do not rule out specific side effects of bromocriptine treatment. Their equal distribution does, however, suggest that not only was allocation to treatment double-blind but also that the treatment remained double-blind throughout. We conclude that bromocriptine, in the dose and duration used in this trial, is of no value in unexplained primary infertility.
Introduction
Raised intracranial pressure has been assumed to be a cause of hypopituitarism since Simonds and Brandes described pituitary necrosis in a patient with a frontal glioma in 1926.1 Many other reports of tumours and head injuries causing hypopituitarism followed.2 The intermittent bursts of intracranial hypertension associated with normal-pressure hydrocephalus seemed instrumental in producing pituitary failure in one patient.3 We carried out this study to ascertain the incidence of endocrinological damage among such patients.
Patients and methods
Normal-pressure hydrocephalus was diagnosed in six patients on the basis of the history; clinical findings; pressure of cerebrospinal fluid (CSF); and results of a radioiodinated serum albumin scan, computerised axial tomography (CAT), and air studies. The patients (three men, three women) were aged 41-64 years (mean 55-2 years), and their histories were as follows.
Case 1-A 41-year-old man with a history of seven years' progressive mental deterioration, four years' gait disturbance, and six months' urinary incontinence. A CAT scan showed dilatation of the ventricular system with no increase in the subarachnoid space over the cortex, and air ventriculography showed that air could not be manoeuvred above the tentorium. Monitoring of the intraventricular pressure showed normal pressure over most of the 24 hours with rises exceeding 300 mm
